Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sreus A.G. Naidu, Roger A. Clemens & A. Satyanarayan Naidu. (2023) SARS-CoV-2 Infection Dysregulates Host Iron (Fe)-Redox Homeostasis (Fe-R-H): Role of Fe-Redox Regulators, Ferroptosis Inhibitors, Anticoagulants, and Iron-Chelators in COVID-19 Control. Journal of Dietary Supplements 20:2, pages 312-371.
Read now
Read now
Tamanna Kabir, Saeed Anwar, Jarin Taslem Mourosi, Shanjida Akter & Mohammad Jakir Hosen. (2023) α- and β-Globin Gene Mutations in Individuals with Hemoglobinopathies in the Chattogram and Sylhet Regions of Bangladesh. Hemoglobin 47:1, pages 3-10.
Read now
Read now
Mindy M. Hugo & Ipsita A. Banerjee. (2019) Development of new amphiphilic bio-organic assemblies for potential applications in iron-binding and targeting tumor cells. Soft Materials 17:1, pages 57-76.
Read now
Read now
Amal El-Beshlawy, Baba Inusa, David Beneitez Pastor, Blanca Xicoy, Maria Soledada Duran Nieto, Andreas Bruederle, Amin Azmon, Geralyn Gilotti & Mohsen Elalfy. (2019) International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting. Hematology 24:1, pages 238-246.
Read now
Read now
Anna W Chalmers & Jamile M Shammo. (2016) Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Therapeutics and Clinical Risk Management 12, pages 201-208.
Read now
Read now
Cheng-Hsu Chen, Kuo-Hsiung Shu & Youngsen Yang. (2015) Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload. Hematology 20:5, pages 304-310.
Read now
Read now
Liat Vazana-Barad, Galit Granot, Rahav Mor-Tzuntz, Itai Levi, Martin Dreyling, Ilana Nathan & Ofer Shpilberg. (2013) Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leukemia & Lymphoma 54:4, pages 851-859.
Read now
Read now